article · Baylor University Medical Center Proceedings
Ezetimibe plus statin therapy demonstrated superior lipid-lowering efficacy compared with double-dose statin therapy, with no additional clinical benefit. There was no difference in overall adverse events. There was a higher incidence of severe adverse events with combination therapy compared to double-dose statin therapy, although these events were rare and not believed to be attributable to medication.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.1080/08998280.2025.2487966
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
